Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBITDA (2016 - 2025)

Vanda Pharmaceuticals' EBITDA history spans 16 years, with the latest figure at -$40.1 million for Q4 2025.

  • For Q4 2025, EBITDA fell 299.84% year-over-year to -$40.1 million; the TTM value through Dec 2025 reached -$150.1 million, down 277.43%, while the annual FY2025 figure was -$150.1 million, 277.43% down from the prior year.
  • EBITDA for Q4 2025 was -$40.1 million at Vanda Pharmaceuticals, down from -$31.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $12.7 million in Q2 2021 and bottomed at -$40.8 million in Q1 2025.
  • The 5-year median for EBITDA is -$6.3 million (2023), against an average of -$7.6 million.
  • The largest annual shift saw EBITDA surged 4628.32% in 2021 before it tumbled 493.42% in 2024.
  • A 5-year view of EBITDA shows it stood at $9.0 million in 2021, then dropped by 23.46% to $6.9 million in 2022, then tumbled by 199.9% to -$6.9 million in 2023, then crashed by 45.41% to -$10.0 million in 2024, then tumbled by 299.84% to -$40.1 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's EBITDA are -$40.1 million (Q4 2025), -$31.0 million (Q3 2025), and -$38.2 million (Q2 2025).